Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | Recent developments in the mutational landscape and molecular basis of AML

In the last 5 years, there has been an increase in our understanding of the molecular basis of acute myeloid leukemia (AML) and in particular, meticulous stratification of the mutational landscape at diagnosis. Charles Craddock, CBE, FRCP, FRCPath, DPhil, from the Queen Elizabeth Hospital, Birmingham, UK takes us through some of these advances, including improved mutational analysis, characterization of the clonal structure of residual disease and identification of novel targets (as for example the RATIFY trial that lead to the approval of midostaurin), and improving patient outcome after allogeneic stem cell transplant. Recorded at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.